Daniel Soffer: ApoA-1 vs HDL-C as Markers of Cardiovascular Risk
Pablo Corral Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared a post on LinkedIn about a recent article by Selin Bilgic et al., published in Journal of Clinical Lipidology, adding:
“ApoA-1 versus HDL-C as markers of cardiovascular risk
HDL-C or ApoA-1:which better reflects cardiovascular risk?
A new analysis from nearly 300,000 UK Biobank participants revisits one of the oldest debates in lipidology:
Key findings:
- ApoA-1 and HDL-C showed similarly strong inverse associations with ASCVD risk
- ApoA-1 explained most of the protective signal traditionally attributed to HDL-C
- Triglycerides contributed far less than expected
- HDL biology may still matter more than many currently assume
Interesting message from this paper:
The story of HDL is probably more nuanced than simply saying ‘HDL is not causal.’
Negative HDL-raising trials did not kill the biology.
They only killed simplistic pharmacology.”
Daniel soffer, Associate Professor of Medicine at University of Pennsylvania, shared this post on LinkedIn:
“Pablo Corral, as usual your posts and commentary are brilliant.
Clearly, HDL is important and clearly, we are measuring what it does poorly.
Manipulating its cholesterol content in serum and even how many HDL particles are in circulation is not the secret.
Perhaps we will figure out how to manipulate HDL for good one day beyond eating healthy, exercising regularly, managing sleep and stress.”
Title: ApoA-1 versus HDL-C as markers of cardiovascular risk
Authors: Selin Bilgic, Karol Pencina, Michael Pencina, Line Dufresne, George Thanassoulis, Allan Sniderman
Stay updated with Hemostasis Today.
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026